Download all the datasets for Covid-19 in BindingDB:  
BindingDB_Covid-19_2D_202406_sdf.zip
BindingDB_Covid-19_3D_202406_sdf.zip
BindingDB_Covid-19_202406_tsv.zip

  1. PMID
    Data
    Article Title
    Citation
    Organization
    Deposition
    Files Download
  2. Spiropyrrolidine derived antiviral agentsBDB
    US Patent US11912714 (2024)
    Enanta Pharmaceuticals, Inc.
    05/03/24
  3. Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of SARS virusBDB
    US Patent US11905306 (2024)
    Southern Research Institute
    04/24/24
  4. Advances in research on 3C-like protease (3CLEBI
    NA
    Huaqiao University
    04/22/24
  5. Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors.EBI
    NA
    Sichuan University
    04/22/24
  6. Insights into targeting SARS-CoV-2: design, synthesis, EBI
    NA
    Egyptian Russian University
    04/22/24
  7. Design and synthesis of naturally-inspired SARS-CoV-2 inhibitors.EBI
    NA
    Institut Pasteur
    04/22/24
  8. Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety.EBI
    NA
    An Hui University of Traditional Chinese Medicine
    04/22/24
  9. Potential treatment methods targeting 2019-nCoV infection.EBI
    NA
    Southern Medical University
    04/21/24
  10. Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2.EBI
    NA
    European Biomedical Research Institute of Salerno (Ebris)
    04/21/24
  11. Easy access to ?-ketoamides as SARS-CoV-2 and MERS MEBI
    NA
    University of Naples Federico Ii
    04/21/24
  12. Fight against novel coronavirus: A perspective of medicinal chemists.EBI
    NA
    Jadavpur University
    04/21/24
  13. COVID-19 therapy: What weapons do we bring into battle?EBI
    NA
    Universidade De Pernambuco
    04/19/24
  14. Identification of Natural Products Inhibiting SARS-CoV-2 by Targeting Viral Proteases: A Combined in Silico and in Vitro Approach.EBI
    NA
    University of Vienna
    04/19/24
  15. Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors.EBI
    NA
    Istituto Italiano Di Tecnologia
    04/18/24
  16. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.EBI
    NA
    University of Palermo
    04/18/24
  17. The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.EBI
    NA
    American University of Ras Al Khaimah
    04/18/24
  18. A review of the latest research on MEBI
    RSC Med Chem 12: 1026-1036 (2021)
    Nantong University
    04/18/24
  19. COMPOUNDS FOR THE TREATMENT OF SARSBDB
    US Patent US20240043417 (2024)
    Purdue Research Foundation
    04/12/24
  20. INHIBITORS OF POSITIVE STRAND RNA VIRUSESBDB
    US Patent US20240033256 (2024)
    National Health Research Institutes
    04/04/24
  21. PYRAZOLO DERIVATIVES AS HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITORS FOR USE AS ANTIVIRALSBDB
    US Patent US20240034730 (2024)
    Drug Discovery and Clinic
    04/04/24
  22. COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONSBDB
    US Patent US20240016777 (2024)
    Beth Israel Deaconess Medical Center
    03/12/24
  23. Alkyne-containing antiviral agentsBDB
    US Patent US11858945 (2024)
    Enanta Pharmaceuticals
    02/22/24
  24. RNA VIRUS INHIBITOR COMPOUNDS WITH IMPROVED METABOLIC STABILITY AND USES THEREOFBDB
    US Patent US20230399296 (2023)
    The Governors of The University of Alberta
    02/03/24
  25. 3-TETRAZOLYLMETHYL-1,3,5-TRIAZIN-2,4-DIONE COMPOUND INHIBITING CORONAVIRUS 3CL PROTEASE ACTIVITY AND PREPARATION METHOD AND USE THEREOFBDB
    US Patent US20230391736 (2023)
    Shaanxi Panlong Pharmaceutical Co.
    01/28/24
  26. Compounds for the treatment of SARSBDB
    US Patent US11795159 (2023)
    Purdue Research Foundation
    12/05/23
  27. Compounds and pharmaceutical uses thereofBDB
    US Patent US11793823 (2023)
    SyneuRx International (Taiwan)
    12/05/23
  28. NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTSBDB
    US Patent US20230331734 (2023)
    Enanta Pharmaceuticals
    12/01/23
  29. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.BDB
    Science 382: (2023)
    Cornell University
    11/27/23
  30. RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOFBDB
    US Patent US20230312571 (2023)
    Fujian Akeylink Biotechnology
    11/13/23
  31. Protease inhibitors as antiviralsBDB
    US Patent US11753373 (2023)
    Acea Therapeutics
    10/20/23
  32. SARS-CoV-2 inhibitors for treating coronavirus infectionsBDB
    US Patent US11731944 (2023)
    Insilico Medicine Ip
    09/26/23
  33. Enzyme inhibition as a potential therapeutic strategy to treat COVID-19 infection.EBI
    Bioorg Med Chem 48: (2021)
    Kingston University
    06/26/23
  34. Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine.EBI
    J Med Chem 65: 7682-7696 (2022)
    University of Oxford
    06/25/23
  35. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.EBI
    J Med Chem 65: 6499-6512 (2022)
    Shionogi
    06/25/23
  36. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease.EBI
    J Med Chem 65: 7818-7832 (2022)
    Wichita State University
    06/25/23
  37. The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities.EBI
    J Med Chem 64: 3508-3545 (2021)
    Niddk
    06/24/23
  38. Bisubstrate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase.EBI
    ACS Med Chem Lett 13: 1477-1484 (2022)
    University of Minnesota
    06/24/23
  39. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.EBI
    J Med Chem 65: 2848-2865 (2022)
    The University of Arizona
    06/24/23
  40. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.EBI
    J Med Chem 65: 16902-16917 (2022)
    Shandong University
    06/24/23
  41. Novel Coronavirus Main Protease Di- and Tripeptide Inhibitors for Treating COVID-19.EBI
    ACS Med Chem Lett 13: 1388-1389 (2022)
    Experimental Drug Development Centre
    06/24/23
  42. Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.EBI
    J Med Chem 65: 16252-16267 (2022)
    China Pharmaceutical University
    06/24/23
  43. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.EBI
    Eur J Med Chem 231: (2022)
    Shanghai Institute of Materia Medica
    06/24/23
  44. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLEBI
    Eur J Med Chem 228: (2022)
    Shanghai University of Traditional Chinese Medicine
    06/24/23
  45. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (MEBI
    Bioorg Med Chem Lett 66: (2022)
    University of Colorado
    06/23/23
  46. Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.EBI
    Eur J Med Chem 238: (2022)
    Peking University
    06/23/23
  47. The Natural Products Withaferin A and Withanone from the Medicinal Herb EBI
    J Nat Prod 85: 2340-2350 (2022)
    Shiv Nadar University
    06/23/23
  48. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.EBI
    Bioorg Med Chem Lett 62: (2022)
    Australian National University
    06/23/23
  49. Discovery of highly potent SARS-CoV-2 MEBI
    Bioorg Med Chem Lett 58: (2022)
    Nanjing University of Chinese Medicine
    06/23/23
  50. Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir.EBI
    J Med Chem 65: 8686-8698 (2022)
    Texas A&M University
    06/23/23
  51. A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir.EBI
    ACS Med Chem Lett 13: 1345-1350 (2022)
    Experimental Drug Development Centre
    06/23/23
  52. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.EBI
    J Med Chem 65: 2716-2746 (2022)
    University of Naples "Federico Ii
    06/22/23
  53. Novel Halomethylketone Azadipeptides for Treating COVID-19.EBI
    ACS Med Chem Lett 13: 875-876 (2022)
    A*Star
    06/22/23
  54. Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.EBI
    J Med Chem 65: 9376-9395 (2022)
    Eberhard Karls University T£Bingen
    06/22/23
  55. Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.EBI
    J Med Chem 65: 955-982 (2022)
    Eberhard Karls University T£Bingen
    06/22/23
  56. Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.EBI
    J Med Chem 65: 7561-7580 (2022)
    The State University of New Jersey
    06/22/23
  57. Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity.EBI
    ACS Med Chem Lett 13: 855-864 (2022)
    University of Perugia
    06/22/23
  58. Target-Based Virtual Screening and LC/MS-Guided Isolation Procedure for Identifying Phloroglucinol-Terpenoid Inhibitors of SARS-CoV-2.EBI
    J Nat Prod 85: 327-336 (2022)
    Kunming Institute of Botany
    06/22/23
  59. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.EBI
    Eur J Med Chem 238: (2022)
    Nankai University
    06/22/23
  60. Tuaimenal A, a Meroterpene from the Irish Deep-Sea Soft Coral EBI
    J Nat Prod 85: 1315-1323 (2022)
    University of South Florida
    06/21/23
  61. Oral Nonpeptidic, Noncovalent Triazine Coronavirus Main Protease Inhibitors for Treating COVID-19.EBI
    ACS Med Chem Lett 13: 1394-1396 (2022)
    Experimental Drug Development Centre
    06/21/23
  62. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.EBI
    RSC Med Chem 12: 1722-1730 (2021)
    University of Alberta Edmonton
    06/21/23
  63. Chemo- and Site-Selective Lysine Modification of Peptides and Proteins under Native Conditions Using the Water-Soluble Zolinium.EBI
    J Med Chem 65: 11840-11853 (2022)
    Chinese Academy of Sciences
    06/21/23
  64. Aspulvins A-H, Aspulvinone Analogues with SARS-CoV-2 MEBI
    J Nat Prod 85: 878-887 (2022)
    Yunnan University
    06/21/23
  65. Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases.EBI
    Eur J Med Chem 240: (2022)
    Heidelberg University
    06/20/23
  66. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.EBI
    J Med Chem 65: 13852-13865 (2022)
    Kyushu University
    06/20/23
  67. Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease.EBI
    J Med Chem 65: 13328-13342 (2022)
    Bio-Techne (Tocris)
    06/20/23
  68. Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.EBI
    Bioorg Med Chem Lett 72: (2022)
    New York University Abu Dhabi
    06/20/23
  69. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.EBI
    Eur J Med Chem 240: (2022)
    Texas A&M University
    06/20/23
  70. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.EBI
    Eur J Med Chem 240: (2022)
    Texas A&M University
    06/20/23
  71. Advanced approaches of developing targeted covalent drugs.EBI
    RSC Med Chem 13: 1460-1475 (2022)
    College of Pharmacy
    06/19/23
  72. Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.EBI
    Eur J Med Chem 240: (2022)
    Mazandaran University of Medical Sciences
    06/19/23
  73. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.EBI
    Bioorg Med Chem 29: (2021)
    Jadavpur University
    06/18/23
  74. Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.EBI
    J Med Chem 65: 13343-13364 (2022)
    Shandong University
    06/18/23
  75. Two Binding Sites of SARS-CoV-2 Macrodomain 3 Probed by Oxaprozin and Meclomen.EBI
    J Med Chem 65: 15227-15237 (2022)
    University of Science and Technology of China
    06/18/23
  76. Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.EBI
    J Nat Prod 84: 161-182 (2021)
    University of California San Diego
    06/18/23
  77. Anti-SARS-CoV-2 Activity of EBI
    J Nat Prod 84: 1261-1270 (2021)
    Mahidol University
    06/18/23
  78. 3-triazolyl methyl-1,3,5-triazine-2,4-dione compounds and preparation method and application thereofBDB
    US Patent US11612603 (2023)
    Shaanxi Panlong Pharmaceutical
    05/09/23
  79. Protacs targeting coronavirus 3CL protease and preparation method and application thereofBDB
    US Patent US11530195 (2022)
    Shaanxi Panlong Pharmaceutical
    02/16/23
  80. Inhibitors of cysteine proteases and methods of use thereofBDB
    US Patent US11524940 (2022)
    Pardes Biosciences
    02/12/23
  81. Protacs based on VHL ligand targeting coronavirus 3CL protease and preparation method and application thereofBDB
    US Patent US11518759 (2022)
    Shaanxi Panlong Pharmaceutical
    02/05/23
  82. ETHER-LINKED ANTIVIRAL COMPOUNDSBDB
    WIPO WO2022208262 (2022)
    Pfizer
    01/31/23
  83. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASESBDB
    WIPO WO2022224223 (2022)
    Novartis
    01/31/23
  84. CORONAVIRUS MAIN PROTEASE INHIBITORS AND METHODS USING SAMEBDB
    WIPO WO2023004291 (2023)
    Baylor College of Medicine
    01/31/23
  85. Inhibitors of cysteine proteases and methods of use thereofBDB
    US Patent US11472793 (2022)
    Pardes Biosciences
    12/24/22
  86. SARS-COV-2 MPRO INHIBITOR COMPOUNDSBDB
    WIPO WO2022129953 (2022)
    Heptares Therapeutics
    10/05/22
  87. Spiropyrrolidine derived antiviral agentsBDB
    US Patent US11339170 (2022)
    Enanta Pharmaceuticals
    08/29/22
  88. Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.EBI
    Eur J Med Chem 223: (2021)
    Chinese Academy of Medical Science and Peking Union Medical College
    08/23/22
  89. Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases.EBI
    Bioorg Med Chem Lett 43: (2021)
    Bristol University
    08/20/22
  90. Discovery and structural optimization of 3-O-?-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections.EBI
    Eur J Med Chem 215: (2021)
    South China Agricultural University
    08/19/22
  91. Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors.EBI
    Bioorg Med Chem Lett 50: (2021)
    Australian National University
    08/19/22
  92. Inhibitors of cysteine proteases and methods of use thereofBDB
    US Patent US11312704 (2022)
    Pardes Biosciences
    08/06/22
  93. ANTIVIRAL HETEROARYL KETONE DERIVATIVESBDB
    WIPO WO2022013684 (2022)
    Pfizer
    06/09/22
  94. NOVEL CORONAVIRUS MAIN PROTEASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOFBDB
    WIPO WO2022021841 (2022)
    Sichuan University
    06/09/22
  95. PHOSPHOLIPID COMPOUNDS AND USES THEREOFBDB
    WIPO WO2022081973 (2022)
    Gilead Sciences
    05/24/22
  96. Potent Inhibition of SARS-CoV-2 nsp14 BDB
    J Med Chem 65: 6231-6249 (2022)
    University of Montpellier
    05/17/22
  97. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.BDB
    Nature (2022)
    University of British Columbia
    03/30/22
  98. Aminocarbamoyl compounds for the treatment of viral infectionsBDB
    WIPO WO2022043374 (2022)
    F. Hoffmann-La Roche
    03/30/22
  99. Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).EBI
    J Med Chem 63: 13205-13227 (2020)
    South China Agricultural University
    03/27/22
  100. Druggable targets from coronaviruses for designing new antiviral drugs.EBI
    Bioorg Med Chem 28: (2020)
    Federal University of Alagoas
    03/27/22
  101. Substituted nucleosides, nucleotides and analogs thereofBDB
    US Patent US11149049 (2021)
    Janssen Biopharma
    03/13/22
  102.  
    Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19BDB
    bioRxiv 2022: (2022)
    Shionogi
    02/02/22
  103. Perspectives on SARS-CoV-2 Main Protease Inhibitors.BDB
    J Med Chem 64: 16922-16955 (2021)
    Michigan State University
    01/27/22
  104. Sars-cov-2 inhibitors having covalent modifications for treating coronavirus infectionsBDB
    WIPO WO2021219089 (2021)
    Insilico Medicine Ip
    01/27/22
  105. Inhibitors of cysteine proteases and methods of use thereofBDB
    US Patent US11124497 (2021)
    Pardes Biosciences
    01/13/22
  106. Nitrile-containing antiviral compoundsBDB
    WIPO WO2021250648 (2021)
    Pfizer
    01/13/22
  107. Compounds and method of treating covid-19BDB
    WIPO WO2021205290 (2021)
    Pfizer
    01/13/22
  108. Compounds and methods for the treatment of covid-19BDB
    WIPO WO2021205298 (2021)
    Pfizer
    01/13/22
  109. Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity.BDB
    J Am Chem Soc 143: 20697-20709 (2021)
    The University of Arizona
    01/13/22
  110. Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.BDB
    J Med Chem (2021)
    University of Illinois At Chicago
    11/05/21
  111. Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.BDB
    J Med Chem 64: 14702-14714 (2021)
    Purdue University
    11/05/21
  112.  
    An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19BDB
    Science 374: 1-13 (2021)
    Pfizer
    11/05/21
  113. A patent review on SARS coronavirus main protease (3CLpro) inhibitors.BDB
    ChemMedChem (2021)
    Experimental Drug Development Centre
    11/05/21
  114.  
    Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor TherapeuticsBDB
    bioRxiv 2021: (2021)
    Israel Institution of Biological Research
    11/05/21
  115. DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 MBDB
    Proc Natl Acad Sci U S A 118: (2021)
    Baylor College of Medicine
    09/11/21
  116. Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.BDB
    ACS Med Chem Lett 12: 1325-1332 (2021)
    Yale University
    09/10/21
  117. Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.BDB
    ACS Pharmacol Transl Sci 4: 1408-1421 (2021)
    The University of Arizona
    09/10/21
  118. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLBDB
    J Med Chem 65: 2880-2904 (2021)
    Cleveland Clinic
    08/14/21
  119. Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-?-lactamases.EBI
    J Med Chem 63: 7491-7507 (2020)
    Qpex Biopharma
    08/13/21
  120. A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.BDB
    Bioorg Med Chem Lett 48: 128263 (2021)
    A*Star
    07/29/21
  121. Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease.BDB
    J Med Chem 64: 10047-10058 (2021)
    Wichita State University
    07/29/21
  122. Peptidomimetic ?-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and BDB
    J Med Chem (2021)
    University of Alberta
    07/29/21
  123. Highly active compounds against COVID-19BDB
    US Patent US10874687 (2020)
    Atea Pharmaceuticals
    07/25/21
  124. N4-hydroxycytidine and derivatives and anti-viral uses related theretoBDB
    US Patent US10874683 (2020)
    Emory University
    07/25/21
  125. SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse modelBDB
    Science (2021)
    Sichuan University
    02/28/21
  126.  
    Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation CalculationsBDB
    ACS Cent Sci (2021)
    Yale University
    02/28/21
  127. Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling.EBI
    Bioorg Med Chem 27: 1981-1989 (2019)
    University of Illinois At Chicago
    02/24/21
  128. The Other Angiotensin II Receptor: ATEBI
    J Med Chem 63: 1978-1995 (2020)
    Centre Hospitalier Universitaire Vaudois (Chuv) and University of Lausanne (Unil
    02/21/21
  129.  
    Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screenBDB
    bioRxiv 2020: (2020)
    Fraunhofer Institute For Translational Medicine and Pharmacology (Itmp) and Fraunhofer Cluster of Excellence For Immune Mediated Diseases (Cimd
    01/31/21
  130. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease InhibitorsBDB
    ChemMedChem (2020)
    Texas A&M University
    01/31/21
  131. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesisBDB
    WIPO WO2006061714 (2006)
    Pfizer
    01/31/21
  132.  
    Inhibition of SARS-CoV-2 main protease by allosteric drug-bindingBDB
    bioRxiv 2020: (2020)
    Center For Free-Electron Laser Science
    01/31/21
  133. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.BDB
    Sci Transl Med 12: 1-15 (2020)
    University of North Carolina At Chapel Hill
    11/13/20
  134. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.BDB
    Antimicrob Agents Chemother 64: (2020)
    Institut Pasteur Korea
    11/13/20
  135. The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.BDB
    Med Res Rev (2020)
    University of Bonn
    11/07/20
  136. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.BDB
    J Med Chem 59: 6595-628 (2016)
    University of Bonn
    11/07/20
  137. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesisBDB
    WIPO WO2005113580 (2005)
    Pfizer
    10/17/20
  138. Broad-spectrum non-covalent coronavirus protease inhibitorsBDB
    US Patent US9975885 (2018)
    Purdue Research Foundation
    09/25/20
  139. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.BDB
    bioRxiv (2020)
    National Institutes of Health
    09/21/20
  140. Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19.BDB
    bioRxiv (2020)
    Pfizer
    09/21/20
  141.  
    Discovery of potent inhibitors of PLproCoV2 by screening a library of selenium-containing compoundsBDB
    bioRxiv 1-12 (2020)
    University Ofamsterdam
    09/21/20
  142. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved ?-ketoamide inhibitors.BDB
    Science 368: 409-412 (2020)
    University of Lubeck
    09/21/20
  143. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.BDB
    Science 368: 1331-1335 (2020)
    Shanghai Institute of Materia Medica
    09/21/20
  144. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.BDB
    ACS Infect Dis 6: 2099-2109 (2020)
    University of Georgia
    09/21/20
  145. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.BDB
    Cancer Discov 4: 1310-25 (2014)
    Fred Hutchinson Cancer Research Center
    09/21/20
  146. Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease.BDB
    Biochem Biophys Res Commun 333: 194-9 (2005)
    National Taiwan University
    09/21/20
  147. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.BDB
    Sci Transl Med 12: (2020)
    Wichita State University
    09/06/20
  148. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors BDB
    Nature 582: 289-293 (2020)
    Shanghaitech University
    09/06/20
  149. Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors.EBI
    Bioorg Med Chem 22: 292-302 (2014)
    Tianjin University of Science and Technology
    09/02/20
  150. Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings.EBI
    Bioorg Med Chem 22: 167-77 (2014)
    University of Illinois At Chicago
    09/02/20
  151. Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava.EBI
    Bioorg Med Chem 21: 3730-7 (2013)
    Korea Research Institute of Bioscience and Biotechnology
    09/01/20
  152. Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors.EBI
    Bioorg Med Chem Lett 23: 6317-20 (2013)
    Kansas State University
    09/01/20
  153. Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases.EBI
    Eur J Med Chem 59: 1-6 (2013)
    The Chinese University of Hong Kong
    08/31/20
  154. Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.EBI
    Bioorg Med Chem 18: 7849-54 (2010)
    Academia Sinica
    08/28/20
  155. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.EBI
    Bioorg Med Chem 18: 7940-7 (2010)
    Korea Research Institute of Bioscience and Biotechnology
    08/28/20
  156. Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.EBI
    Bioorg Med Chem 17: 5139-45 (2009)
    National Human Genome Research Institute
    08/27/20
  157. SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii.EBI
    Bioorg Med Chem Lett 20: 1873-6 (2010)
    Korea Research Institute of Bioscience and Biotechnology
    08/27/20
  158. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.EBI
    Bioorg Med Chem Lett 19: 2722-7 (2009)
    Kyoto Pharmaceutical University
    08/27/20
  159. Novel small-molecule inhibitors of transmissible gastroenteritis virus.EBI
    Antimicrob Agents Chemother 51: 3924-31 (2007)
    National Health Research Institute
    08/27/20
  160. Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors.EBI
    Bioorg Med Chem Lett 17: 5876-80 (2007)
    Purdue University
    08/24/20
  161. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.EBI
    Eur J Med Chem 150: 334-346 (2018)
    Wichita State University
    08/16/20
  162. Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors.EBI
    Bioorg Med Chem 24: 3035-3042 (2016)
    Academia Sinica
    09/14/17
  163. Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia.BDB
    J Enzyme Inhib Med Chem 29: 59-63 (2014)
    Gyeongsang National University
    08/28/17
  164. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.BDB
    ACS Chem Biol 10: 1456-65 (2015)
    University of Illinois At Chicago
    10/15/15
  165. Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid- hydrolysis.EBI
    Eur J Med Chem 79: 184-93 (2014)
    University of Lille
    02/07/15
  166. Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite.EBI
    Bioorg Med Chem Lett 18: 732-7 (2008)
    Glaxosmithkline
    05/21/13
  167. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.EBI
    Bioorg Med Chem 20: 5928-35 (2012)
    Korea Research Institute of Bioscience and Biotechnology
    05/17/13
  168. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.BDB
    J Biol Chem 284: 7646-55 (2009)
    National Yang-Ming University
    10/29/12
  169. Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT.EBI
    Bioorg Med Chem Lett 21: 4860-4 (2011)
    Philipps University Marburg
    03/23/12
  170. Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.EBI
    Bioorg Med Chem Lett 21: 3088-91 (2011)
    Chonnam National University
    12/04/11
  171. Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease.BDB
    Chem Biol 13: 261-8 (2006)
    Academia Sinica
    07/07/11
  172. Phage-encoded combinatorial chemical libraries based on bicyclic peptides.EBI
    Nat Chem Biol 5: 502-7 (2009)
    Laboratory of Molecular Biology, Medical Research Council
    06/10/11
  173. Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives.EBI
    Bioorg Med Chem Lett 19: 4538-41 (2009)
    Konkuk University
    08/27/10
  174. Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase/helicase.EBI
    Bioorg Med Chem Lett 19: 1636-8 (2009)
    Konkuk University
    01/11/10
  175. Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite.EBI
    Bioorg Med Chem Lett 18: 1681-7 (2008)
    Glaxosmithkline
    11/11/09
  176. Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors.EBI
    J Med Chem 48: 6767-71 (2005)
    Purdue University
    11/10/09
  177. Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters.EBI
    J Med Chem 50: 1850-64 (2007)
    University of Alberta
    11/10/09
  178. Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.EBI
    J Med Chem 49: 3440-3 (2006)
    Peking University
    11/10/09
  179. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors.EBI
    Bioorg Med Chem Lett 15: 3058-62 (2005)
    Development Center For Biotechnology
    11/10/09
  180. Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease.BDB
    J Med Chem 52: 5228-40 (2009)
    Purdue University
    09/14/09
  181. Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits.BDB
    Bioorg Med Chem 16: 4138-49 (2008)
    University of Mississippi
    07/08/08
  182. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.BDB
    J Med Chem 49: 3485-95 (2006)
    National Tsing Hua University
    09/26/06
  183. Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters.BDB
    Bioorg Med Chem 13: 5240-52 (2005)
    National Taiwan University
    09/26/06
  184. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.BDB
    J Med Chem 49: 5154-61 (2006)
    National Defense Medical Center
    09/26/06
  185. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.BDB
    J Med Chem 48: 4469-73 (2005)
    National Taiwan University
    09/26/06
  186. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.BDB
    J Med Chem 49: 4971-80 (2006)
    Taigen Biotechnology
    09/23/06
BDB Curated by BindingDB
ChEMBL Curated by ChEBML